6 Analysts Have This to Say About Macrogenics
Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter:
Guggenheim Downgrades Macrogenics to Neutral
Guggenheim analyst Chalres Zhu downgrades Macrogenics (NASDAQ:MGNX) from Buy to Neutral.
HC Wainwright & Co. Maintains Buy on Macrogenics, Lowers Price Target to $35
HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $41 to $35.
Macrogenics: Q1 Earnings Insights
Macrogenics (NASDAQ:MGNX) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Macrogenics missed estimated earnings by 25.58%, reporting an EPS of $-1.08 versus an estimate of $-0.86.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Citigroup Upgrades Macrogenics to Buy, Lowers Price Target to $21
Citigroup analyst Yigal Nochomovitz upgrades Macrogenics (NASDAQ:MGNX) from Neutral to Buy and lowers the price target from $23 to $21.
93 Biggest Movers From Friday
Gainers
Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90.